Composition for beneficially influencing Alzheimer's disease and/or for Alzheimer's prophylaxis

Abstract

The invention relates to a composition for Alzheimer's prophylaxis and/or for therapeutic treatment of pre-existing symptoms of the type of Alzheimer's disease comprising a mixture of VLCFA3, in particular based on montan waxes and/or derivatives thereof or Guerbet acids or the corresponding components of carnauba wax, shellac or policosanols or VLCFA3 from natural waxes, where appropriate in combination with physiologically tolerated copper salts such as copper orotate and in combination with DMAE. The composition can be administered orally according to the invention as food additive or as beverage.

Description

Claims

1. A composition for Alzheimer's prophylaxis or for the therapeutic treatment of pre-existing symptoms of the Alzheimer's disease comprising at least one component from VLCFA3, wherein the chain length of the hydrocarbon radicals in the VLCFA3 component being in the range from 14 to 40 C atoms and the carboxylic acidse optionally comprising amounts in the range from 0 to 10 mol % of unbranched dicarboxylic acids.

2. The composition as claimed in claim 1, wherein the VLCFA3 component includes at least one VLCFA based on montan waxes or derivatives thereof or of Guerbet acids or the corresponding components of carnauba wax or shellac or at least one VLCFA from natural waxes.

3. The composition as claimed in claim 1 further comprising a physiologically tolerated copper salt.

4. The composition as claimed in claim 1 further comprising dimethylaminoethanol.

5. The composition as claimed in claim 1, further comprising a physiologically tolerated copper salt and dimethylaminoethanol.

6. A process for Alzheimer's prophylaxis or for the therapeutic treatment of preexisting symptoms of the Alzheimer's disease comprising the step of administering, on a daily basis, a therapeutically effective amount of a composition as claimed in claim 1, which is employed in a daily dose of from 1 to 1000 mg, based on the amount of the VLCFA3 component.

7. A process for Alzheimer's prophylaxis or for the therapeutic treatment of preexisting symptoms of the Alzheimer's disease comprising the step of administering, on a daily basis, a therapeutically effective amount of a composition as claimed in claim 4, wherein the therapeutically effective amount includes from 0 to 10 mg of a physiologically tolerated copper salt, and from 1 to 170 mg of dimethylaminoethanol.

8. A food additive comprising a therapeutically effective amount of a composition as claimed in claim 1.

9. The composition as claimed in claim 1, wherein the at least one component from VLCFA3 is based on montan waxes or derivatives thereof, Guerbet acids or Guerbet alcohols, the corresponding components of carnauba wax, shellac, or policosanols and mixtures thereof.

10. The composition as claimed in claim 1, wherein the chain length of the hydrocarbon radicals in the VLCFA3 component are in the range from 28 to 40 C atoms.

11. The composition as claimed in claim 1, wherein the number is C atoms in the VLCFA3 component is an even number.

12. The composition as claimed in claim 4, wherein the physiologically tolerated copper salt is copper orotate.

13. The process as claimed in claim 6, wherein the daily dose is from 5 to 500 mg.

14. The process as claimed in claim 6, wherein the daily dose is from 5 to 100 mg.

15. The process as claimed in claim 7, wherein the therapeutically effective amount includes from 1 to 10 mg of the physiologically tolerated copper salt.

16. The process as claimed in claim 7, wherein the physiologically tolerated copper salt is copper orotate.

17. A process for Alzheimer's prophylaxis or for the therapeutic treatment of pre-existing symptoms of the Alzheimer's disease comprising the step of administering, on a daily basis, a therapeutically effective amount of a composition as claimed in claim 3, wherein the therapeutically effective amount includes 1 to 10 mg of the physiologically tolerated copper salt and 0 to 200 mg of dimethylaminoethanol.

18. The process as claimed in claim 18, wherein the therapeutically effective amount includes from 1 to 170 mg of the dimethylaminoethanol.

19. A beverage comprising a therapeutically effective amount of a composition as claimed in claim 1, wherein the composition is emulsified.